IN2013CH04135A - - Google Patents

Info

Publication number
IN2013CH04135A
IN2013CH04135A IN4135CH2013A IN2013CH04135A IN 2013CH04135 A IN2013CH04135 A IN 2013CH04135A IN 4135CH2013 A IN4135CH2013 A IN 4135CH2013A IN 2013CH04135 A IN2013CH04135 A IN 2013CH04135A
Authority
IN
India
Prior art keywords
virus
culture
bulk
inactivated
virus bulk
Prior art date
Application number
Other languages
English (en)
Inventor
Krishna Mohan Vadrevu
Ramasamy Venkatesan
Kumar Duvuru Prasanna
Original Assignee
Bharat Biotech Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Biotech Int Ltd filed Critical Bharat Biotech Int Ltd
Priority to PCT/IN2014/000585 priority Critical patent/WO2015059714A1/en
Priority to AU2014338520A priority patent/AU2014338520B2/en
Priority to RU2016114285A priority patent/RU2706693C2/ru
Priority to CN201480050520.1A priority patent/CN105744952A/zh
Priority to IN4135CH2013 priority patent/IN2013CH04135A/en
Publication of IN2013CH04135A publication Critical patent/IN2013CH04135A/en
Priority to PH12016500500A priority patent/PH12016500500A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN4135CH2013 2013-09-14 2014-09-08 IN2013CH04135A (enExample)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PCT/IN2014/000585 WO2015059714A1 (en) 2013-09-14 2014-09-08 Emergency mode in a hybrid vehicle
AU2014338520A AU2014338520B2 (en) 2013-09-14 2014-09-08 A viral vaccine and methods of manufacture thereof
RU2016114285A RU2706693C2 (ru) 2013-09-14 2014-09-08 Вирусная вакцина и способы ее производства
CN201480050520.1A CN105744952A (zh) 2013-09-14 2014-09-08 病毒疫苗及其制备方法
IN4135CH2013 IN2013CH04135A (enExample) 2013-09-14 2014-09-08
PH12016500500A PH12016500500A1 (en) 2013-09-14 2016-03-14 A viral vaccine and methods of manufacture thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN4135CH2013 IN2013CH04135A (enExample) 2013-09-14 2014-09-08

Publications (1)

Publication Number Publication Date
IN2013CH04135A true IN2013CH04135A (enExample) 2015-08-14

Family

ID=52997726

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4135CH2013 IN2013CH04135A (enExample) 2013-09-14 2014-09-08

Country Status (6)

Country Link
CN (1) CN105744952A (enExample)
AU (1) AU2014338520B2 (enExample)
IN (1) IN2013CH04135A (enExample)
PH (1) PH12016500500A1 (enExample)
RU (1) RU2706693C2 (enExample)
WO (1) WO2015059714A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
CA2992531C (en) * 2015-07-16 2023-09-26 Bharat Biotech International Limited Vaccine compositions
US11162880B2 (en) 2015-11-09 2021-11-02 University Of Notre Dame Du Lac Particle size purification method and devices
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
MY202505A (en) 2017-11-03 2024-05-01 Takeda Vaccines Inc Zika vaccines and immunogenic compositions, and methods of using the same
SG11202003975WA (en) 2017-11-30 2020-06-29 Takeda Vaccines Inc Method for inactivating zika virus and related methods
EP3581646A1 (en) * 2018-06-15 2019-12-18 Themis Bioscience GmbH Integrated manufacturing and chromatographic system for virus production
CA3107770C (en) 2018-08-16 2023-09-05 Emd Millipore Corporation Closed bioprocessing device
CN111394321A (zh) * 2020-03-30 2020-07-10 无锡加莱克色谱科技有限公司 病毒颗粒纯化用超大孔径层析介质及其应用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122009000037I2 (de) * 1997-08-28 2011-06-16 Cheil Jedang Corp Ein an vero-zellen angepasstes abgeschwächtes japanisches enzephalitis virus und ein impfstoff gegen japanische enzephalitis
KR20120027381A (ko) * 2009-05-25 2012-03-21 파나세아 바이오테크 리미티드 일본뇌염 백신 및 그것의 제조 방법
CN102100910B (zh) * 2009-12-21 2013-01-23 北京清大天一科技有限公司 一种生产病毒疫苗的方法
CN103228293A (zh) * 2010-11-30 2013-07-31 巴拉特生物技术国际有限公司 用于在哺乳动物中预防和治疗金迪普拉病毒感染的疫苗制剂
WO2013130001A1 (en) * 2012-02-29 2013-09-06 Ge Healthcare Bio-Sciences Ab Method for endotoxin removal

Also Published As

Publication number Publication date
CN105744952A (zh) 2016-07-06
RU2016114285A3 (enExample) 2018-07-16
AU2014338520B2 (en) 2019-12-05
AU2014338520A1 (en) 2016-03-31
RU2706693C2 (ru) 2019-11-20
WO2015059714A8 (en) 2015-06-18
RU2016114285A (ru) 2017-10-19
WO2015059714A1 (en) 2015-04-30
PH12016500500A1 (en) 2016-06-13

Similar Documents

Publication Publication Date Title
PH12016500500A1 (en) A viral vaccine and methods of manufacture thereof
AU2018256640A1 (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
PH12018501602A1 (en) Subunit immersion vaccines for fish
PH12013502442A1 (en) Inactivated dengue virus vaccine
MX2018010483A (es) Inmunogenos para vacunacion contra vih.
PH12015501526A1 (en) Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using same
JO3517B1 (ar) ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
MA39819A (fr) Méthodes et compositions d'immunomodulation
HK1222205A1 (zh) 由多能干细胞产生的光感受器和光感受器袓细胞
MX2017007196A (es) Fibroblastos de embrion de pollo inmortalizados.
MY192824A (en) Compound targeting il-23a and tnf-alpha and uses thereof
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
MY191539A (en) Streptococcal vaccine
EA201790847A1 (ru) Композиции и способы лечения с применением пролекарств тизоксанида, его аналога или соли
BR112017009790A2 (pt) anticorpos direcionados ao anti-ang2 e métodos de uso
MX2020012893A (es) Formulaciones de proteinas.
ZA202000574B (en) Mesenchymal stem cells as vaccine adjuvants and methods for using the same
EP3010340A4 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
MX2016014868A (es) Metodos para secar por congelacion y rehidratar productos biologicos.
MX2019007924A (es) Vacunas contra la influenza.
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
IN2013MU02813A (enExample)
IN2013CH05865A (enExample)
WO2014188212A3 (en) Treatment and prevention of malaria
WO2014174532A3 (en) An improved process for the preparation of emtricitabine